Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study - Supplement

Published: 4 June 2021| Version 2 | DOI: 10.17632/sd554hbbjb.2
Contributors:
Brett King,
Justin Ko,
Seth Forman,
Manabu Ohyama,
Natasha Mesinkovska,
Guanglei Yu,
Jill McCollam,
Margaret Gamalo,
Jonathan Janes,
Edson-Heredia Emily,
Katrin Holzwarth,
Yves Dutronc

Description

Supplemental material for manuscript published in the Journal for the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2021.05.050

Files